Can Fite Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Can Fite Stock Summary

Can Fite competes with ImmuCell, Compugen, Evogene, Collplant Biotechnologies, and Protalix Biotherapeutics. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people.

Can Fite Key Financial Ratios

Can Fite Key Balance Sheet Accounts

Can Fite Key Income Statement Accounts

Can Fite Key Cash Accounts

Can Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Can Fite's current stock value. Our valuation model uses many indicators to compare Can Fite value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Can Fite competition to find correlations between indicators driving Can Fite's intrinsic value. More Info.Can Fite Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Can Fite's Return On Equity is most likely to slightly decrease in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Can Fite by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Can Fite Biopharma Systematic Risk

Today, most investors in Can Fite Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Can Fite's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Can Fite growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Can Fite help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Can Fite Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Can Fite Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Can Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Can Fite's daily price indicators and compare them against related drivers.

When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.